个人简历

张强 973首席科学家，北京市重点实验室主任，创新团队负责人。1982年毕业于北京医学院，1995年在华西医科大学获得博士学位，1982-1992年就职于医药总局四川抗菌素工业研究所，先后任课题组长、研究室副主任；1989-1990年在日本国福冈大学药学部工作；1995年就职于北京医科大学（北京大学），先后任药剂教研室主任、药剂系主任，药学院副院长等。\r
\r
现任中国药学会常务理事、中国药学会药剂专业委员会名誉主任委员、中国药学会纳米药物专业委员会副主任委员、国家药典会委员制剂专业委员会副主任、国家重大科学研究计划首席科学家、中国药学杂志（中英文版）和药学学报（中英文版）副主编、 J Controlled Release 等国际杂志编委等。曾任世界控释协会（CRS）中国分会首任主席、中国药学会药剂专委会主任委员、国家重点室副主任等

研究领域

""分子药剂学与创新制剂临床转化，包括难溶药物、抗癌药物、大分子药物的新型递送系统的基础研究与临床转化""""

近期论文

Wang, Xiaoyou; Zhang Qiang, et al. Anisotropy in Shape and Ligand-Conjugation of Hybrid Nanoparticulates Manipulates the Mode of Bio-Nano Interaction and Its Outcome. Advanced Functional Materials . 2017, 27 (31)\r
\r
Dai, Wenbing; Zhang Qiang, et al. Combination antitumor therapy with targeted dual-nanomedicines. Advanced Drug Delivery Reviews . 2017, 115: 23-45\r
\r
Liang, Yanqin; Zhang Qiang, et al. A Nanosystem of Amphiphilic Oligopeptide- Drug Conjugate Actualizing Both alpha v beta 3 Targeting and Reduction-Triggered Release for Maytansinoid. Theranostics . 2017,7(13): 3306-3318\r
\r
Gao Wei; Zhang Qiang, et al. The use of electronic-neutral penetrating peptides cyclosporin A to deliver pro-apoptotic peptide: A possibly better choice than positively charged TAT. Journal of Controlled Release . 2017, 261: 174-186\r
\r
Li, Suxin; Zhang Qiang, et al. Novel Biological Functions of ZIF-NP as a Delivery Vehicle: High Pulmonary Accumulation, Favorable Biocompatibility, and Improved Therapeutic Outcome. Advanced Functional Materials . 2016, 26(16): 2715-2727\r
\r
Wang, Dan; Zhang Qiang, et al. The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model. Journal of Controlled Release . 2016, 238: 186-196\r
\r
Fu JJ, Zhang Q, et al. Macrophage mediated biomimetic delivery system for the treatment of lung metastasis of breast cancer, Journal of Controlled Release , 2015,204:11-19\r
\r
Hu Hongxiang, Zhang Hua, Zhang Qiang, et al. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel. Journal of Controlled Release , 2015,220:189-200\r
\r
Guo Z, Zhang Q, et al. Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering. Biomaterials . 2014 Jul; 35(23):6106-17.\r
\r
Qin C, Zhang Q, et al. The impact of a chlorotoxin-modified liposome system on receptor MMP-2 and the receptor-associated protein ClC-3. Biomaterials . 2014 Jul;35(22):5908-20.